Organigram Global (OGI) Cash & Current Investments (2018 - 2026)
Organigram Global (OGI) posted quarterly Cash & Current Investments of -$33.1 million for Q1 2026, up 31.53% year-over-year from -$25.1 million in Q1 2025, and down 650.36% quarter-over-quarter from $6.0 million in Q4 2025.
Organigram Global (OGI) Cash & Current Investments (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Cash & Current Investments for 9 consecutive years, with -$33.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments rose 31.53% year-over-year to -$33.1 million; the TTM figure through Mar 2026 stood at -$33.1 million (up 49.71% YoY), while the FY2025 annual figure was -$33.7 million, changed N/A from the prior year.
- Cash & Current Investments declined to -$33.1 million in Q1 2026 per OGI's latest filing, from $6.0 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $97.2 million in Q3 2024 and bottomed at -$48.3 million in Q1 2025.
- Historically, Cash & Current Investments has averaged $10.6 million across 5 years, with a median of $13.4 million in 2022.
- Annual changes were most pronounced in 2022 — Cash & Current Investments tumbled 88.65% — and 2024, when it surged 151.78%.
- Organigram Global's Cash & Current Investments stood at $20.8 million in 2022, then jumped by 85.38% to $38.6 million in 2023, then sank by 145.22% to -$17.5 million in 2024, then surged by 134.43% to $6.0 million in 2025, then tumbled by 650.36% to -$33.1 million in 2026.
- Business Quant data shows OGI's Cash & Current Investments at -$33.1 million in Q1 2026, $6.0 million in Q4 2025, and $21.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Organigram Global | 151.93 Mn | 151.81 Mn | 28.97 Mn | 120,318.94 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.08 Mn |
| Dec 31, 2025 | 6.01 Mn |
| Sep 30, 2025 | 21.09 Mn |
| Mar 31, 2025 | -48.31 Mn |
| Dec 31, 2024 | -17.46 Mn |
| Sep 30, 2024 | 97.21 Mn |
| Sep 30, 2023 | 38.61 Mn |
| Aug 31, 2022 | 20.83 Mn |
| Nov 30, 2021 | 69.01 Mn |
| Aug 31, 2021 | 183.56 Mn |
| May 31, 2021 | 106.95 Mn |
| Feb 28, 2021 | 71.12 Mn |
| Nov 30, 2020 | 133.90 Mn |
| Aug 31, 2020 | 56.11 Mn |
| May 31, 2020 | 32.02 Mn |
| Feb 29, 2020 | 41.24 Mn |
| Aug 31, 2019 | 287,429.99 |
| Aug 31, 2018 | 55.06 Mn |